<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">SEIDL, DANIEL</style></author><author><style face="normal" font="default" size="100%">JANSSEN, STEFAN</style></author><author><style face="normal" font="default" size="100%">STROJAN, PRIMOZ</style></author><author><style face="normal" font="default" size="100%">HAKIM, SAMER G.</style></author><author><style face="normal" font="default" size="100%">WOLLENBERG, BARBARA</style></author><author><style face="normal" font="default" size="100%">SCHILD, STEVEN E.</style></author><author><style face="normal" font="default" size="100%">RADES, DIRK</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Importance of Chemotherapy and Radiation Dose After Microscopically Incomplete Resection of Stage III/IV Head and Neck Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2487-2491</style></pages><volume><style face="normal" font="default" size="100%">36</style></volume><issue><style face="normal" font="default" size="100%">5</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: To investigate the importance of chemotherapy and radiation dose after R1 resection of squamous cell carcinoma of the head-and-neck (SCCHN). Patients and Methods: One hundred and twenty-two patients receiving radiotherapy alone or with concurrent chemotherapy [cisplatin or cisplatin/5-fluorouracil (5-FU)] were retrospectively analyzed. Results: On multivariate analysis, chemotherapy was significantly associated with improved locoregional control (p=0.048). Three-year locoregional control rates were 61% for those treated without chemotherapy, 83% for those treated with cisplatin and 77% for those treated with cisplatin/5-FU. Radiation doses of 66 and 70 Gy were non-significantly superior to 60-64 Gy (p=0.18). On multivariate analysis, chemotherapy showed a trend for improving survival (p=0.055). Three-year OS rates were 51% for those without chemotherapy, 65% for those treated with cisplatin and 57% for those treated with cisplatin/5-FU. Radiation doses of 66 Gy (3-year survival=61%) and 70 Gy (70%) were superior to 60-64 Gy (25%) (p=0.021). Conclusion: Concurrent chemotherapy and a radiation dose of 66 Gy resulted in better outcomes. Cisplatin and cisplatin/5-FU were similarly effective. Radiation doses &gt;66 Gy appear not to be necessary.</style></abstract></record></records></xml>